We analyzed aging parameters using a mechanistic target of rapamycin (mTOR) 
INTRODUCTION
Inhibiting target of rapamycin (TOR) activity appears to extend lifespan in various model systems, including yeast, worms, and flies (Bjedov et al., 2010; Kaeberlein et al., 2005; Kapahi et al., 2004; Medvedik et al., 2007; Vellai et al., 2003) . Moreover, deletion of the TOR1 gene in yeast results in an increase in replicative lifespan that cannot be further extended by nutrient restriction (Kaeberlein et al., 2005) . Evidence also suggests that mechanistic TOR (mTOR) plays a role in regulating mammalian lifespan.
Treatment of mice beginning at 20 months of age with rapamycin, a pharmacological inhibitor of mTOR, results in an extension of lifespan that averages 9% for males and 13% for females (Harrison et al., 2009) . When rapamycin was initiated at 9 months of age, median survival was increased to 10% for males and 18% for females (Miller et al., 2011) . Similarly, deletion of ribosomal S6 protein kinase 1 (S6K1), a downstream effector of mTOR, extends the median lifespan of female S6K1 À/À mice by approximately 19% (Selman et al., 2009) . Very recently, an additional genetic model consisting of mice heterozygous for deletion of both mTOR and mLST8 (mammalian lethal with Sec13 protein 8) also demonstrated lifespan extension, again only evident in female mice (Lamming et al., 2012) . In mammals, mTOR exists in two distinct complexes, termed mTORC1 and mTORC2. Each of these mTOR complexes has distinct protein components, although both share the catalytic mTOR subunit, as well as mLST8 (Dazert and Hall, 2011; Laplante and Sabatini, 2012; Zoncu et al., 2011) . Agents such as rapamycin are known to acutely inhibit mTORC1, although chronic treatment can also affect the activity of mTORC2 (Lamming et al., 2012; Sarbassov et al., 2006) . How reducing mTOR activity extends lifespan remains incompletely understood. In addition, whether manipulations of pathways that regulate mammalian lifespan will slow aging and age-related pathologies in a uniform or segmental fashion remains largely unexplored. Here, using a genetic model of reduced mTOR expression, we provide evidence that reducing mTOR activity produces a marked increase in overall lifespan while also regulating an important, but not universal, subset of tissue-specific, age-dependent parameters.
RESULTS

Reduced mTOR Expression Increases Survival
To assess the role of mTOR in mammalian aging, we used a model of hypomorphic mTOR expression that has been recently described (Zhang et al., 2011) . This model results from a floxed neomycin cassette inserted between exons 12 and 13 of the mTOR locus that results in the partial disruption of mTOR transcription ( Figure 1A ). While complete disruption of Raptor, Rictor, mLST8, or mTOR is embryonically lethal (Gangloff et al., 2004; Guertin et al., 2006; Murakami et al., 2004) analyzed, levels of TORC1 and TORC2 complexes appeared to be reduced to a similar degree ( Figure S1B ). As expected, mTOR D/D MEFs had reduced activation of S6 kinase following leucine addition ( Figure 1C) , although the overall level of protein translation was not altered ( Figure S1C ). We noted that mTOR
mice also exhibited a decrease in mTOR signaling in vivo. In particular, the activation of S6 kinase following insulin administration was markedly attenuated in mTOR D/D mice ( Figure 1D ).
Similarly, the mTORC2 dependent serine 473 phosphorylation of Akt was also reduced in these mice. We next asked whether this reduction in mTOR activity was sufficient to provide an extension in lifespan. Median survival of the mTOR D/D male mice was significantly higher than observed in mTOR +/+ (WT) male mice ( Figure 1E ; median survival for WT, (H) Incidence of malignant tumors found at necropsy denoted by shaded portion of each bar. While the overall incidence of cancer was different between the two genotypes, the spectrum of tumors observed was similar. **p < 0.001, Fisher's exact test. See also Figure S1 .
the observed median survival for WT female mice was 26.5 months (n = 24), whereas for female mTOR D/D mice (n = 26), median survival was 31.5 months ( Figure 1F ; 19% extension, p = 0.047 by log rank test Figure 1G ). We also assessed whether mTOR D/D mice had an increase in maximal lifespan by using the number of mice in each group that were still alive after 90% of the pooled distribution of WT and the mTOR D/D mice were dead (Wang et al., 2004 Mice involved in the lifespan analysis were not subject to any physiological testing and received no treatment except if they developed a visible superficial infection. In such cases, the facility staff provided a short course of oral, subcutaneous, or topical antibiotics with or without ibuprofen (5 of 34 WT and 10 of 43 mTOR D/D mice received some treatment). If the infection persisted or worsened, to the point the mouse was felt to be in significant pain or functionally impaired, then the mouse was euthanized. In some older mice, the initial superficial infection was not discovered until it had progressed to such a degree that the staff believed the condition was too severe to respond to standard treatment, and, as such, the animal was euthanized without any prior treatment. We noted that the percentage of mice euthanized because of severe or progressive superficial infections was much higher in the mTOR 
No Alterations in Glucose Homeostasis or Metabolism in the mTOR
Analysis of body size ( Figure 2A ) and body weight ( Figure 2B ) revealed that mTOR D/D mice were consistently smaller than their WT littermates, although normalized body composition was unchanged ( Figure S2A ). When food intake was normalized to body weight, mTOR D/D mice and WT mice consumed equivalent amount of calories ( Figure 2C ). While rapamycin treatment in mice results in alteration in glucose homeostasis (Cunningham et al., 2007; Lamming et al., 2012) , analysis of young mTOR
mice revealed no significant alterations in glucose tolerance (Figure 2D) or insulin sensitivity ( Figure 2E ). Indeed, while a reduction in insulin signaling is associated with increased lifespan (Kenyon, 2011) , fasting levels of insulin were slightly higher in the mTOR Figure S2B ). This appeared to relate in part to a cell-autonomous increase in insulin secretion from pancreatic islets isolated from mTOR D/D mice ( Figures S2C and S2D ). Analysis of older WT and mTOR D/D mice revealed that there was also no marked difference in glucose tolerance as these mice aged ( Figure S2E ). Serum analysis revealed no significant differences in various lipid parameters ( Figures S2F, S2G , and S2H). Finally, the respiratory exchange ratio ( Figure 2F ), in vivo fatty acid oxidation rates ( Figure 2G ), the overall metabolic rate ( Figure 2H ), and normalized energy expenditure ( Figure 2I ) were all unaltered in mTOR D/D mice. Thus, as previously observed, the lifespan extension observed by reducing mTOR expression does not appear to result from a significant alteration in energetic or metabolic parameters (Lamming et al., 2012) .
Biomarkers of Aging Are Reduced in the mTOR D/D Mice
When compared to a cohort of young mice, we observed a significant increase in p16 Ink4A mRNA in the tissues of old WT mice (Krishnamurthy et al., 2004 We next assessed the balance and coordination using a Rotarod apparatus. We noted no difference in this functional parameter between young WT and mTOR D/D mice ( Figure 4C ).
When compared to young WT mice, older WT mice were unable to remain as long on the spinning Rotarod apparatus. This is again consistent with the known decrement in balance and coordination as mice age (Barreto et al., 2010) . Again, this decline in performance was significantly less marked in the mTOR D/D mice ( Figures 4C and S4A ). We observed a similar pattern when we assessed gait parameters of the mice. Stride width variability has been closely associated with falls in the elderly population (Hausdorff et al., 2001; Maki, 1997) . Again, this parameter was similar in our cohorts of young WT and mTOR D/D mice ( Figure 4D ).
As WT mice aged, stride width variability, an integrative measure of neurological, muscular, and postural control, increased. Again, this change was less evident in mTOR D/D mice ( Figure 4D ). Similarly, assessment of grip strength, a measure of muscle strength, demonstrated that, once again, mTOR D/D mice were protected from an age-dependent decline in function ( Figure 4E ). While the mTOR D/D mice appeared to have slower decline in various age-dependent parameters, this was not universally true. Measurement of bone volume revealed that the age-dependent decrease in trabecular bone volume was actually more pronounced in the mTOR D/D mice ( Figure 4F ). Similarly, we noted that mTOR hypomorphic mice suffered a significant increase in the age-dependent increase in infections that predominantly affected the mouth, eye, and skin ( Figure 4G ). Thus, it appears that, in contrast to the other functional parameters measured, the age-dependent decline in bone volume and immune function were seemingly exacerbated in the mTOR D/D mice. All pooled data are presented as mean ± SEM. *p < 0.05. **p < 0.01. See also Figure S3 .
DISCUSSION
In summary, we describe a genetic model for reduced mTOR expression and activity that results in a robust increase in lifespan. The magnitude of lifespan extension in our model was larger than previously observed when mice were given rapamycin (Harrison et al., 2009 ). There are numerous possibilities that might explain these differences. First, in the initial report using rapamycin, the drug was initiated at 20 months of age. This contrasts with our model in which our genetic reduction of mTOR activity begins in the embryo. Indeed, a subsequent study, in which rapamycin was initiated at 9 months of age, saw slightly larger effects on lifespan (Miller et al., 2011) . Another possibility is that the reduction in mTOR activity was greater in our model than can be achieved in animals treated pharmacologically. It should be noted that, while mTOR mice were viable, when we bred mTOR +/D mice, we consistently generated less than 25% of pups that were mTOR
. This suggests that the reduction in mTOR expression we observed is close to what may be the lower limit needed for embryonic viability. Another possibility is that rapamycin is primarily an inhibitor of mTORC1 activity, although, as noted, with chronic administration it can have effects on mTORC2 activity as well (Lamming et al., 2012; Sarbassov et al., 2006) . In contrast, our model leads to a balanced reduction in both mTORC1 and mTORC2 activity. Finally, it is important to note that we were dealing with a relatively small cohort of mice and that the observed median survival of our WT mice cohort (26.2 months) is on the short end of the published spectrum. As such, the precise magnitude of lifespan extension seen with the mTOR D/D mice must be viewed with caution until it is replicated in other facilities.
Our data suggest that a number of molecular, biochemical, and functional parameters of aging were reduced or slowed in the mTOR D/D mice. This is consistent with the notion that reducing mTOR expression does indeed slow the entire aging process in mammals (Wilkinson et al., 2012) . Of note, our data clearly indicate that not all age-related parameters are regulated in an mTOR-dependent fashion. While the age-dependent increase in infection observed in mTOR D/D mice are likely related to the known role of mTOR in immune function (Chi, 2012; Zhang et al., 2011) , these immune effects are less likely to explain the observed accelerated decline in bone volume in mTOR
mice. Perhaps more relevant is a set of recent observations suggesting a role for mTOR in modulating the age-dependent decline in bone mass (Xian et al., 2012) . Finally, recent data suggest that long-term rapamycin treatment may accelerate cataract formation and augment testicular degeneration (Wilkinson et al., 2012) . While these parameters were not part of our standard necropsy analysis, we did a separate analysis for a limited number of WT and mTOR D/D mice. While we saw no evidence for alterations in the testes ( Figures S4B and S4C ), our preliminary data are consistent with a potential role for mTOR activity in delaying cataract formation ( Figure S4D ). Taken together, our observations suggest that single individual genetic pathways that extend lifespan will likely have nonuniform effects on the rate that individual tissues manifest their age-dependent decline in function. One interpretation of these observations would be that tissue aging and organismal aging are governed by interconnected but separable regulatory control mechanisms. One potential analogy might be circadian rhythms, whereby multiple distinct and independent peripheral clocks coexist in a confederation with a stronger central clock. In a similar fashion, our data suggest the interesting possibility that the rate of tissue aging may be viewed as influenced by, but not completely subservient to, the rate of organismal aging. Alternatively, our results could suggest the possibility that some interventions that slow aging may also have unintended, negative tissue-specific side effects. A very relevant precedent perhaps already exists for this phenomenon, as people who undergo voluntary caloric restriction appear to have a corresponding reduction in their bone mineral density (Villareal et al., 2011) . Further analysis of this and related genetic models should help distinguish between these possibilities and, we hope, will help guide potential therapies aimed at extending lifespan and health span in people.
EXPERIMENTAL PROCEDURES Mice
The generation of mTOR D/D mice has been previously described (Zhang et al., 2011 For genotype analysis, tissues were analyzed by PCR primers and conditions as described elsewhere (Zhang et al., 2011) . Unless stated otherwise, young mice represent those that are between 3 and 6 months in age, and old mice represent those between 17 and 27 months in age. Specific ages, number, and sex of mice used varied and are listed under the relevant specific test.
Lifespan Analysis
For the determination of lifespan, male and female mTOR +/+ and mTOR
mice were housed in a specific pathogen-free (SPF) facility. This means that mice entering the facility must be pathogen free with the exception of the specific pathogens Helicobacter, mouse parvovirus, or mouse norovirus. Mice were maintained in microisolator cages in ventilated racks with high-efficiency particulate air (or HEPA)-filtered supply and exhaust air. All cages were opened and changed inside biosafety cabinets or clean air hoods using microisolator technique. Mice were fed a regular chow diet consisting of 24% of calories derived from protein, 14% from fat, and 62% from carbohydrates (NIH-31/Harlan Teklad diet). Mice of different genotypes (mTOR +/+ and mTOR D/D mice)
were housed together, but male and female mice were maintained in separate cages. The maximum density was five mice per cage. The only withdrawal of mice from the study occurred within the first 6 months, when a limited number of WT and mTOR D/D male mice were excluded because of excessive fighting.
Time of death is calculated using the date mice were found dead, or the time when the mice were determined to be moribund and/or displaying such severe discomfort that veterinary technicians recommended euthanasia. We sought to perform full autopsies on every mouse at the time of their withdrawal from the study; however, for various logistical reasons, a small fraction of mice of each genotype were not expeditiously forwarded to the pathologist 
